Leif Marz
Family · Honolulu, HINPI 1659982726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Gilead at 30.2% of the total. Reporting peaked in 2023 at $3,350 and has fallen 76.4% since, to $790 in 2025. Among family clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$2K
- Indivior Inc.$1K
- AbbVie$1K
- Boehringer Ingelheim$379
- Novo Nordisk$357
- plus $2K from 18 others
What the payments were for
- Food & beverage$10,57299%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 197 | $3,224 |
| Viiv Healthcare Company | 68 | $2,382 |
| Indivior Inc. | 45 | $1,285 |
| AbbVie | 42 | $1,002 |
| Boehringer Ingelheim | 16 | $379 |
| Novo Nordisk | 3 | $357 |
| Johnson & Johnson(2 entities) | 17 | $351 |
| Alkermes, Inc. | 11 | $308 |
| Otsuka America Pharmaceutical, Inc. | 5 | $249 |
| Teva Pharmaceuticals USA, Inc. | 9 | $229 |
| Janssen Products, LP | 2 | $213 |
| Amarin Pharma, Inc. | 3 | $140 |
| Merck | 7 | $135 |
| Lilly USA, LLC | 2 | $127 |
| Novartis | 2 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Insulet Corporation | 1 | $33 |
| Dexcom, Inc. | 2 | $32 |
| GSK | 1 | $28 |
| EMD Serono, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $21 |
| Bayer | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Organon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,672 in reported general payments places this provider in the 95th percentile of 466 family providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabenuvaCabotegravir/Rilpivirine | 18 | $76,732 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 14 | $66,683 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $53,926 |
| JulucaDolutegravir/Rilpivirine | 13 | $46,165 |
| PerserisRisperidone | 12 | $34,226 |
| OzempicSemaglutide | 24 | $32,263 |
| Abilify MaintenaAripiprazole | 12 | $31,776 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $28,101 |
| TrulicityDulaglutide | 14 | $19,824 |
| EliquisApixaban | 21 | $19,527 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $13,743 |
| JardianceEmpagliflozin | 18 | $12,336 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,937 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $3,528 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyCabenuva, Juluca | $2,382 | $122,89731 claims |
| GileadBiktarvy, Descovy | $3,224 | $82,02725 claims |
| Janssen Products, LPSymtuza | $213 | $66,68314 claims |
| Indivior Inc.Perseris | $1,285 | $34,22612 claims |
| Novo NordiskOzempic | $357 | $32,26324 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $249 | $31,77612 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance | $379 | $26,07946 claims |
| Lilly USA, LLCTrulicity | $127 | $19,82414 claims |
| GSKIncruse Ellipta | $28 | $5,93717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family providers in Hawaii.
Other family in Honolulu
- Joey SesonHonolulu$48K
- Kanna DokgoHonolulu$26K
- John MosesHonolulu$24K
- Ia Lynne AranaHonolulu$9K
- Josette DudoitHonolulu$8K
- Kailie WongHonolulu$6K
- Jane StinsonHonolulu$6K
- Melissa leHonolulu$6K
- Karen RowanHonolulu$6K
- Tate KusatsuHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.